388.4K
XNAS Volume
High volume today
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Frisbee Allison | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 72,900 | 72,900 | - | - | Employee Stock Option (Right to Buy) | |
| Y. Lin Charles | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 72,900 | 72,900 | - | - | Employee Stock Option (Right to Buy) | |
| Norbert W. Bischofberger | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 1.17 per share. | 27 Jun 2024 | 410,848 | 10,597,468 | - | 1.2 | 478,843 | Common Stock |
| Norbert W. Bischofberger | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 1.25 per share. | 27 Jun 2024 | 204,670 | 10,802,138 | - | 1.2 | 254,957 | Common Stock |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Joshua A. Kazam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| David M. Tanen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 11,333 | 25,296 | - | 0 | Common Stock | |
| Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Roshawn A. Blunt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Katherine Vega Stultz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Norbert W. Bischofberger | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 0.88 per share. | 10 Jun 2024 | 1,378,901 | 5,749,395 | - | 0.9 | 1,208,469 | Common Stock |
| Norbert W. Bischofberger | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 1.24 per share. | 10 Jun 2024 | 881,913 | 7,375,616 | - | 1.2 | 1,096,041 | Common Stock |
| Norbert W. Bischofberger | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 10 Jun 2024 | 744,308 | 6,493,703 | - | 1.1 | 814,571 | Common Stock |
| Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 164,260 | 164,260 | - | 0 | Common Stock | |
| Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 246,390 | 246,390 | - | - | Employee Stock Option (Right to Buy) | |
| Allison Frisbee | SR VP, CORP OPERATIONS & LEGAL | Sale of securities on an exchange or to another person at price $ 1.05 per share. | 21 Feb 2024 | 12,105 | 204,510 | - | 1.1 | 12,757 | Common Stock |
| Charles Lin Y. | SR VP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 1.05 per share. | 21 Feb 2024 | 12,036 | 234,603 | - | 1.1 | 12,685 | Common Stock |
| Elizabeth A. Olek | SR VP, CLINICAL SCIENCE | Sale of securities on an exchange or to another person at price $ 1.05 per share. | 21 Feb 2024 | 7,368 | 193,275 | - | 1.1 | 7,765 | Common Stock |
| W. Norbert Bischofberger | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 699,800 | 699,800 | - | - | Employee Stock Option (Right to Buy) | |
| W. Norbert Bischofberger | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 270,339 | 2,811,004 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 1.18 per share. | 04 Jan 2024 | 12,009 | 315,246 | - | 1.2 | 14,214 | Common Stock |
| Dinsmore Christopher | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.18 per share. | 04 Jan 2024 | 7,366 | 260,969 | - | 1.2 | 8,718 | Common Stock |
| Kosacz Barbara | COO & General Counsel | Sale of securities on an exchange or to another person at price $ 1.18 per share. | 04 Jan 2024 | 10,676 | 928,966 | - | 1.2 | 12,636 | Common Stock |
| DiMartino Jorge | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 1.31 per share. | 12 Dec 2023 | 17,367 | 327,255 | - | 1.3 | 22,664 | Common Stock |
| Dinsmore Christopher | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.31 per share. | 12 Dec 2023 | 10,032 | 268,335 | - | 1.3 | 13,092 | Common Stock |
| Yasir B. Al-Wakeel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 06 Jul 2023 | 9,617 | 346,102 | - | 1.8 | 16,852 | Common Stock |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 06 Jul 2023 | 10,818 | 344,622 | - | 1.8 | 18,956 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 06 Jul 2023 | 6,634 | 278,367 | - | 1.8 | 11,625 | Common Stock |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Joshua A. Kazam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| David M. Tanen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 11,333 | 13,963 | - | 0 | Common Stock | |
| Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 5,868 | 5,868 | - | - | Stock Option (Right to Buy) | |
| Roshawn A. Blunt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Marianne De Backer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Katherine Vega Stultz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 7,079 | 7,079 | - | - | Stock Option (Right to Buy) | |
| Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2023 | 68,000 | 68,000 | - | - | Director Stock Option (Right to Buy) | |
| Katherine Vega Stultz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 68,000 | 68,000 | - | - | Director Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.74 per share. | 24 Feb 2023 | 9,026 | 355,719 | - | 1.7 | 15,665 | Common Stock |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 1.74 per share. | 24 Feb 2023 | 10,153 | 355,440 | - | 1.7 | 17,621 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.74 per share. | 24 Feb 2023 | 6,291 | 285,001 | - | 1.7 | 10,918 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 570,868 | 570,868 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 208,367 | 208,367 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 138,911 | 364,745 | - | 0 | Common Stock | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 208,367 | 208,367 | - | - | Employee Stock Option (Right to Buy) | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 138,911 | 939,642 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 137,008 | 365,593 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 205,513 | 205,513 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 179,824 | 179,824 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 119,882 | 291,292 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 12 Dec 2022 | 18,657 | 219,478 | - | 1.8 | 33,680 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 12 Dec 2022 | 9,138 | 162,936 | - | 1.8 | 16,496 | Common Stock |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 53,600 | 216,841 | - | 0 | Common Stock | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 53,600 | 791,624 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,300 | 238,135 | - | 0 | Common Stock | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 43,550 | 172,074 | - | 0 | Common Stock | |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Joshua A. Kazam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 11,333 | 11,333 | - | 0 | Common Stock | |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| David M. Tanen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Elena H. Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Roshawn A. Blunt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | |
| Marianne De Backer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 11,333 | 14,083 | - | 0 | Common Stock | |
| Marianne De Backer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Norbert W. Bischofberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 3.83 per share. | 17 May 2022 | 90,931 | 303,411 | - | 3.8 | 348,529 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 3.72 per share. | 17 May 2022 | 206,198 | 509,609 | - | 3.7 | 768,046 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 3.78 per share. | 17 May 2022 | 300,000 | 809,609 | - | 3.8 | 1,134,510 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 400,000 | 400,000 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 53,600 | 163,241 | - | 0 | Common Stock | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Employee Stock Option (Right to Buy) | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 53,600 | 738,024 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 90,000 | 90,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 60,300 | 177,835 | - | 0 | Common Stock | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 43,550 | 128,524 | - | 0 | Common Stock | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 65,000 | 65,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 12.36 per share. | 13 Dec 2021 | 16,152 | 117,785 | - | 12.4 | 199,687 | Common Stock |
| Jorge DiMartino | Chief Medical Officer & VP | Sale of securities on an exchange or to another person at price $ 12.82 per share. | 13 Dec 2021 | 250 | 117,535 | - | 12.8 | 3,206 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.82 per share. | 13 Dec 2021 | 174 | 84,974 | - | 12.8 | 2,231 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.36 per share. | 13 Dec 2021 | 11,212 | 85,148 | - | 12.4 | 138,614 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 12.08 per share. | 06 Dec 2021 | 14,356 | 212,480 | - | 12.1 | 173,492 | Common Stock |
| Marianne De Backer | Director | Purchase of securities on an exchange or from another person at price $ 11.57 per share. | 01 Dec 2021 | 1,150 | 2,750 | - | 11.6 | 13,306 | Common Stock |
| Roshawn A. Blunt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 41,200 | 41,200 | - | - | Director Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 04 Oct 2021 | 9,189 | 96,360 | - | 20.8 | 191,195 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2021 | 9,189 | 315,308 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 04 Oct 2021 | 9,189 | 105,549 | - | 3.3 | 30,048 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.91 per share. | 07 Sep 2021 | 9,189 | 96,360 | - | 21.9 | 201,302 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 9,189 | 324,497 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 07 Sep 2021 | 9,189 | 105,549 | - | 3.3 | 30,048 | Common Stock |
| Marianne De Backer | Director | Purchase of securities on an exchange or from another person at price $ 19.63 per share. | 20 Aug 2021 | 500 | 1,600 | - | 19.6 | 9,815 | Common Stock |
| Marianne De Backer | Director | Purchase of securities on an exchange or from another person at price $ 19.50 per share. | 20 Aug 2021 | 500 | 1,100 | - | 19.5 | 9,750 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.59 per share. | 02 Aug 2021 | 9,189 | 96,360 | - | 20.6 | 189,165 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2021 | 9,189 | 333,686 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 02 Aug 2021 | 9,189 | 105,549 | - | 3.3 | 30,048 | Common Stock |
| Arie S. Belldegrun | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | |
| Joshua A. Kazam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 5,150 | 5,150 | - | - | Stock Option (Right to Buy) | |
| David M. Tanen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | |
| Otello Stampacchia | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 20,600 | 20,600 | - | - | Stock Option (Right to Buy) | |
| Elena Ridloff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 15,450 | 15,450 | - | - | Stock Option (Right to Buy) | |
| Marianne De Backer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 8,583 | 8,583 | - | - | Stock Option (Right to Buy) | |
| Marianne De Backer | Director | Purchase of securities on an exchange or from another person at price $ 25.01 per share. | 28 May 2021 | 600 | 600 | - | 25.0 | 15,006 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 20.84 per share. | 16 Apr 2021 | 25,292 | 1,344,962 | - | 20.8 | 527,085 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 21.56 per share. | 16 Apr 2021 | 7,870 | 1,337,092 | - | 21.6 | 169,677 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 20.63 per share. | 16 Apr 2021 | 19 | 1,301,537 | - | 20.6 | 392 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 16 Apr 2021 | 21,532 | 1,301,556 | - | 20.1 | 432,793 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 16 Apr 2021 | 4,157 | 1,323,088 | - | 21.4 | 88,877 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 20.25 per share. | 16 Apr 2021 | 9,847 | 1,327,245 | - | 20.3 | 199,402 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 21.78 per share. | 13 Apr 2021 | 24,818 | 1,370,254 | - | 21.8 | 540,536 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 23.10 per share. | 13 Apr 2021 | 18,938 | 1,395,072 | - | 23.1 | 437,468 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 22.38 per share. | 13 Apr 2021 | 13,698 | 1,414,010 | - | 22.4 | 306,561 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 25.18 per share. | 13 Apr 2021 | 1,285 | 1,427,708 | - | 25.2 | 32,356 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 24.40 per share. | 13 Apr 2021 | 5,738 | 1,428,993 | - | 24.4 | 140,007 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 23.35 per share. | 13 Apr 2021 | 9,997 | 1,434,731 | - | 23.4 | 233,430 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 26.27 per share. | 08 Apr 2021 | 15,728 | 1,444,828 | - | 26.3 | 413,175 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 27.21 per share. | 08 Apr 2021 | 100 | 1,444,728 | - | 27.2 | 2,721 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 27.91 per share. | 08 Apr 2021 | 24,816 | 1,482,216 | - | 27.9 | 692,615 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 27.09 per share. | 08 Apr 2021 | 38,312 | 1,507,032 | - | 27.1 | 1,037,872 | Common Stock |
| Jakob Loven | Director | Sale of securities on an exchange or to another person at price $ 27.20 per share. | 08 Apr 2021 | 21,660 | 1,460,556 | - | 27.2 | 589,152 | Common Stock |
| Taiyin Yang | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 41,200 | 41,200 | - | - | Director Stock Option (Right to Buy) | |
| Marianne De Backer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 41,200 | 41,200 | - | - | Stock Option (right to buy) | |
| Norbert W. Bischofberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 198,124 | 198,124 | - | 0 | Common Stock | |
| Norbert W. Bischofberger | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 297,186 | 297,186 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 108,633 | 108,633 | - | - | Employee Stock Option (Right to Buy) | |
| Yasir B. Al-Wakeel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 72,422 | 109,641 | - | 0 | Common Stock | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 104,736 | 104,736 | - | - | Employee Stock Option (Right to Buy) | |
| Barbara Kosacz | COO & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 69,824 | 684,424 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 133,937 | 133,937 | - | 0 | Common Stock | |
| Jorge DiMartino | Chief Medical Officer & VP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 200,906 | 200,906 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 136,665 | 136,665 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Dinsmore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2020 | 91,110 | 96,360 | - | 0 | Common Stock | |
| Arie S. Belldegrun | Director | 14 Oct 2020 | 228,315 | 0 | - | - | Series A Preferred Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 1,304,563 | 0 | - | - | Series A Preferred Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 650,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 173,333 | 0 | - | - | Series Seed Preferred Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 253,251 | 2,315,314 | - | 16.2 | 4,090,004 | Common Stock | |
| Arie S. Belldegrun | Director | 14 Oct 2020 | 1,376,313 | 2,062,063 | - | - | Common Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 685,750 | 685,750 | - | - | Common Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 240,872 | 679,575 | - | - | Common Stock | ||
| Arie S. Belldegrun | Director | 14 Oct 2020 | 182,866 | 438,703 | - | - | Common Stock | ||
| John C. Martin | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 75,800 | 1,952,364 | - | 19 | 1,440,200 | Common Stock |
| John C. Martin | Director | 14 Oct 2020 | 205,260 | 1,876,564 | - | 16.2 | 3,314,949 | Common Stock | |
| John C. Martin | Director | 14 Oct 2020 | 756,971 | 1,671,304 | - | - | Common Stock | ||
| John C. Martin | Director | 14 Oct 2020 | 914,333 | 914,333 | - | - | Common Stock | ||
| John C. Martin | Director | 14 Oct 2020 | 717,509 | 0 | - | - | Series A Preferred Stock | ||
| John C. Martin | Director | 14 Oct 2020 | 866,667 | 0 | - | - | Series Seed Preferred Stock | ||
| Joshua A. Kazam | Director | 14 Oct 2020 | 23,556 | 25,666 | - | - | Common Stock | ||
| Joshua A. Kazam | Director | 14 Oct 2020 | 65,228 | 0 | - | - | Series A Preferred Stock | ||
| Joshua A. Kazam | Director | 14 Oct 2020 | 22,328 | 0 | - | - | Series Seed Preferred Stock | ||
| Joshua A. Kazam | Director | 14 Oct 2020 | 68,815 | 94,481 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 1,651,576 | 4,089,238 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 185,758 | 4,274,996 | - | 16.2 | 2,999,992 | Common Stock | |
| Norbert W. Bischofberger | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 95,500 | 4,370,496 | - | 19 | 1,814,500 | Common Stock |
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 263,750 | 263,750 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 263,750 | 263,750 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 250,000 | 0 | - | - | Series Seed Preferred | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 250,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 250,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 250,000 | 0 | - | - | Series Seed Preferred Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 1,565,475 | 0 | - | - | Series A Preferred Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 300,001 | 0 | - | - | Series Seed Preferred Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 263,750 | 263,750 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 263,750 | 263,750 | - | - | Common Stock | ||
| Norbert W. Bischofberger | Director, President & CEO | 14 Oct 2020 | 316,501 | 2,437,662 | - | - | Common Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 231,553 | 363,428 | - | - | Common Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 233,405 | 365,280 | - | - | Common Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 68,831 | 434,111 | - | - | Common Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 37,119 | 471,230 | - | 16.2 | 599,472 | Common Stock | |
| David M. Tanen | Director | 14 Oct 2020 | 219,482 | 0 | - | - | Series Seed Preferred Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 221,237 | 0 | - | - | Series Seed Preferred Stock | ||
| David M. Tanen | Director | 14 Oct 2020 | 65,243 | 0 | - | - | Series A Preferred Stock | ||
| Otello Stampacchia | Director, Ten Percent Owner | 14 Oct 2020 | 1,304,563 | 0 | - | - | Series A Preferred Stock | ||
| Otello Stampacchia | Director, Ten Percent Owner | 14 Oct 2020 | 1,606,220 | 1,625,671 | - | - | Common Stock | ||
| Otello Stampacchia | Director, Ten Percent Owner | 14 Oct 2020 | 1,376,313 | 3,001,984 | - | - | Common Stock | ||
| Otello Stampacchia | Director, Ten Percent Owner | 14 Oct 2020 | 366,299 | 3,368,283 | - | 16.2 | 5,915,729 | Common Stock | |
| Otello Stampacchia | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 450,000 | 3,818,283 | - | 19 | 8,550,000 | Common Stock |
| Otello Stampacchia | Director, Ten Percent Owner | 14 Oct 2020 | 1,522,484 | 0 | - | - | Series Seed Preferred Stock | ||
| Elena Ridloff | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 2,630 | 2,630 | - | 19 | 49,970 | Common Stock |
| Yasir B. Al-Wakeel | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 5,250 | 37,219 | - | 19 | 99,750 | Common Stock |
| Jakob Loven | Director | 14 Oct 2020 | 1,376,313 | 1,376,313 | - | - | Common Stock | ||
| Jakob Loven | Director | 14 Oct 2020 | 1,304,563 | 0 | - | - | Series A Preferred Stock | ||
| Jakob Loven | Director | 14 Oct 2020 | 169,031 | 1,545,344 | - | 16.2 | 2,729,851 | Common Stock | |
| Barbara Kosacz | COO & General Counsel | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 5,250 | 614,600 | - | 19 | 99,750 | Common Stock |
| Christopher Dinsmore | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 14 Oct 2020 | 5,250 | 5,250 | - | 19 | 99,750 | Common Stock |
| Rebecka Belldegrun | Director | 14 Oct 2020 | 228,315 | 0 | - | - | Series A Preferred Stock | ||
| Rebecka Belldegrun | Director | 14 Oct 2020 | 173,333 | 0 | - | - | Series Seed Preferred Stock | ||
| Rebecka Belldegrun | Director | 14 Oct 2020 | 240,872 | 679,575 | - | - | Common Stock | ||
| Rebecka Belldegrun | Director | 14 Oct 2020 | 182,866 | 438,703 | - | - | Common Stock |